%0 Journal Article
%T Cost-Utility Analysis of Liraglutide in Type 2 Diabetes Patients in China after Chinese Reformation of Medical Care System
%A Gaoyu Xie
%A Suning Zhao
%J Journal of Biosciences and Medicines
%P 13-25
%@ 2327-509X
%D 2018
%I Scientific Research Publishing
%R 10.4236/jbm.2018.612002
%X <b>Objectives</b>: The
cost-utility analysis of Liraglutide is aimed at evaluating whether Liraglutide
is cost-effective or not after Chinese reformation on medical insurance. The
analysis is based on the results of clinical trial conducted in Asia. <b>Methods</b>:
We applied a Markov model to estimate the quality-adjusted life years, medical
cost and incidence of diabetes-related complications for patients receiving the
Liraglutide as an add-on to the metformin treatment. Baseline characteristics
were taken
from a China¡¯s study while the treatment effect is from an Asian study. The
related medical cost and utility score were obtained from a local study in
China. Having set 30 years¡¯ simulations, the incremental cost-effectiveness
ratio was calculated comparing with glimepiride treatment. The ratio would be
compared with the willingness to pay for a quality-adjusted-life-year (QALY)
which is three times of the GDP per capita in Beijing. Sensitivity analysis was
also performed. <b>Result</b>: During a period of 30 years, the base-case
analysis which takes discount rate at 3% shows that Liraglutide 1.8 mg results in an average
incremental cost of CNY 82,671.49, an improvement in 0.12 QALYs and a reduction
of incidence of diabetes-related complications comparing to glimepiride. The
associated incremental cost-effectiveness ratio is CNY 688,929.08. <b>Conclusion</b>:
Long-term project shows that taking Liraglutide as an add-on to the metformin
treatment will lead to increasing quality-adjusted life years and reduction of incidence of diabetes-related
complications. When the price of Liraglutide is reduced by 43 percent in
China¡¯s yuan, Liraglutide will be cost-effective in China from the healthcare
system perspective taking three times of GDP per capita as our WTP threshold.
%K Liraglutide
%K Type 2 Diabetes Mellitus
%K Markov Model
%K Cost-Effectiveness Analysis
%K Chinese Reformation on Medical Insurance
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=88972